CELEXT07 biostimulant enhances grass fertilization and growth
MONTREAL, July 23, 2019 /CNW/ - Mondias Naturals Inc. ("Mondias" or the "Company") (TSXV: NHP) is pleased to announce the first sale of its CELEXTO7 bio-defense stimulant plant extract to MontVert.com, a lawn seed and fertilizing company serving Montreal and the Monteregie region, in Quebec. MontVert.com will use CELEXT07 to enhance the properties of its custom-made fertilizer.
"This first sale is important for Mondias as it continues to show that CELEXT07 can be used in a multitude of applications, including the important fertilizer market segment," said Jean-Philippe Gravel, CEO of Mondias. "It's also important to note that CELEXT07 is already authorized for sale under fertilizer regulations in Canada as a specialty fertilizer. Fertilizer is a growing segment of the overall agricultural industry in Canada, which produces over 25 million metric tons of fertilizer per year, contributing over $12 billion annually to Canada's gross domestic product (Source: Canadian Fertilizer Institute).
"Over the last months, CELEXT07 has generated significant interest from major players in the horticulture, agriculture, hops and cannabis sectors," Mr. Gravel added. "Recent test results for cannabis (see press release dated March 18, 2019) and hops (see press release dated May 16, 2019) were significant milestones in demonstrating the qualities of CELEXT07 for those markets. Moreover, ongoing discussions with several potential customers could lead to further testing and generate additional sales."
"Before buying CELEXT07, we tested the product ourselves and found that CELEXT07 significantly enhanced the properties of our custom-made fertilizer when the two were applied together," said Alec Brazeau, President of MontVert.com. "The tests showed that we could produce grass that was denser, greener and faster growing using less fertilizer. In the next few weeks, we will do other tests to isolate and measure the direct effect of CELEXT07 on our seeds and lawns."
About Mondias Natural Products Inc. Mondias specializes in the commercialization and development of evidence-based botanical products for the health-care, bio-agriculture and organic markets. The company sells both oral and topical botanical agents to help manage unmet medical needs through its Holizen Laboratories division. Mondias is also developing botanical-based specialty fertilizers for use on household plants, lawns and golf courses and in urban gardens, nurseries and greenhouses, in collaboration with McGill's Faculty of Agricultural and Environmental Sciences.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include the Company's inability to obtain sufficient financing to execute its business plan; competition; regulation; anticipated and unanticipated costs and delays; the success of the Company's research and development strategies; the ability to obtain orphan drug status; the applicability of the discoveries made; the successful and timely completion and uncertainties related to the regulatory approval process; the timing of clinical trials; the timing and outcomes of regulatory or intellectual property decisions; and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this news release, and the Company does not undertake any obligation to publicly update them to reflect new information or subsequent events or otherwise unless required by applicable securities legislation.
SOURCE Mondias Natural Products Inc.
For further information: Mondias Natural Products Inc., Jean-Philippe Gravel, Chief Executive Officer, 514-804-4569, [email protected]; Relations Publiques Paradox Inc., 514-341-0408